MDGL - Madrigal Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$731.25
DETAILS
HIGH:
$964.00
LOW:
$571.00
MEDIAN:
$679.00
CONSENSUS:
$731.25
UPSIDE:
41.37%
About Madrigal Pharmaceuticals, Inc. (https://www.madrigalpharma.com)
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| William J. Sibold | Chief Executive Officer, President & Director | 1966 | $2,371,345 USD |
| Rebecca A. Taub | Founder, Senior Scientific & Medical Advisor and Director | 1952 | $1,222,044 USD |
| Mardi C. Dier | Executive Vice President & Chief Financial Officer | 1964 | $1,209,553 USD |
| Carole Huntsman | Executive Vice President & Chief Commercial Officer | 1965 | $1,079,128 USD |
| David Soergel | Executive VP & Chief Medical Officer | 1968 | $1,077,282 USD |
| Shannon Kelley | Executive Vice President, Chief Legal Officer & Corporate Secretary | 1975 | $1,073,105 USD |
| Clint Wallace | Executive Vice President & Chief Human Resources Officer | – | – |
| Mark Underwood | Executive Vice President of Business Planning & Operations | – | – |
| Rita Thakkar | Senior VP & Chief Accounting Officer | 1974 | – |
| Ronald Filippo | Executive Vice President & Chief Information Officer | – | – |
| Tina E. Ventura | Chief Investor Relations Officer | – | – |